. 2018 Apr 30;6(2):35. doi: 10.3390/medsci6020035

Table 6.

ERS/ESCMID Guidelines for the Management and Treatment of Community-Acquired Pneumonia [65].

Low Severity	Moderate—High Severity
CURB-65 to guide outpatient treatment Treatment: * Aminopenicillin ± macrolide * Aminopenicillin/ß-lactamase inhibitora ± macrolide * Non-antipseudomonal cephalosporin II or III + macrolide * Cefotaxime or ceftriaxone ± macrolide * Penicillin G ± macrolide	ICU admission: acute respiratory failure, severe sepsis or septic shock and radiographic extension of infiltrates/ severely decompensated comorbidities No risk factors for Pseudomonas aeruginosa: Non-antipseudomonal cephalosporin III + macrolide or non-antipseudomonal cephalosporin III + moxifloxacin or levofloxacin Risk factors for P. aeruginosa: Antipseudomonal cephalosporin or acyl-ureido-penicillin/ß-lactamase inhibitor or carbapenem (meropenem preferred) plus ciprofloxacin or plus macrolide + aminoglycoside (gentamicin, tobramycin or amikacin)

Low Severity

Moderate—High Severity

CURB-65 to guide outpatient treatment
Treatment:
* Aminopenicillin ± macrolide
* Aminopenicillin/ß-lactamase inhibitora ± macrolide
* Non-antipseudomonal cephalosporin II or III + macrolide
* Cefotaxime or ceftriaxone ± macrolide
* Penicillin G ± macrolide

ICU admission: acute respiratory failure, severe sepsis or septic shock and radiographic extension of infiltrates/ severely decompensated comorbidities
No risk factors for Pseudomonas aeruginosa: Non-antipseudomonal cephalosporin III + macrolide or non-antipseudomonal cephalosporin III + moxifloxacin or levofloxacin
Risk factors for P. aeruginosa: Antipseudomonal cephalosporin or acyl-ureido-penicillin/ß-lactamase inhibitor or carbapenem (meropenem preferred) plus ciprofloxacin or plus macrolide + aminoglycoside (gentamicin, tobramycin or amikacin)

ERS/ESCMID: European Respiratory Society/ European Society of Clinical Microbiology and Infectious Diseases.